Secretome Therapeutics (SecretomeTx) has been recognized with a 2026 Global Recognition Award for its exceptional work in scalable cell therapy manufacturing, translational leadership, and rigorous scientific research that places it among the foremost performers in the Startup Of The Year, Leadership, and Research categories.

SecretomeTx operates at one of biotechnology’s most demanding frontiers, developing off-the-shelf cell-based regenerative therapies for patients living with heart failure and dilated cardiomyopathy. Founded only a few years ago, the company advanced its lead therapeutic candidate, STM-01, a first-in-class cellular therapy derived from neonatal cardiac progenitor cells (nCPCs), through commercial-scale manufacturing and into Phase 1 clinical trials within a compressed timeline that few clinical-stage biotechnology startups achieve. The FDA’s Fast Track designation for STM-01 further validated the therapy’s potential to address a serious unmet medical need, setting a strong foundation for what was to follow.

SecretomeTx dosed its first patient in a Phase 1 study of STM-01 in late 2025, a milestone that reflects not only scientific progress but also the organizational discipline required to move a novel therapeutic from concept to clinic. The company’s partnership with RoosterBio to complete large-scale bioreactor-based production of STM-01, including a 50-liter bioreactor process, confirmed that it had resolved one of regenerative medicine’s most persistent manufacturing challenges. These achievements, taken together, form the basis for recognition spanning scientific merit, operational execution, and startup leadership.

Translating Science Into Clinical Reality

Rachana Mishra, who leads process development and manufacturing strategy at SecretomeTx, has directed studies comparing 2D and 3D cell expansion systems, evaluated cell banking strategies across manufacturing sites, and developed cryopreservation approaches designed to support sustained clinical programs. Her contributions directly enabled the company’s investigational new drug (IND) submissions and clinical development activities, ensuring that scientific discoveries did not stall at the manufacturing stage, where many cell therapy programs falter. This deliberate focus on manufacturing infrastructure, established early in the company’s history, gave SecretomeTx a competitive foundation that supports both its current and future therapeutic programs.

SecretomeTx is simultaneously advancing STM-21, a secretome-based therapeutic derived from STM-01, through preclinical development for neurological conditions, including ALS and diabetic neuropathy, as well as inflammatory skin conditions. This pipeline breadth reflects a deliberate organizational strategy to build a manufacturing platform robust enough to support multiple therapeutic programs, rather than optimizing narrowly for a single asset. Mishra’s work establishing master cell banks, designing comparability studies, and ensuring product consistency across manufacturing platforms has been fundamental to making this multi-program strategy viable, allowing the company to operate with the scientific discipline and manufacturing maturity of a far larger organization.

Leadership, Research, and Scientific Rigor

SecretomeTx’s recognition reflects both the quality of its research output and the leadership model it has built across its scientific and operational teams. The company received the maximum grade of 5, defined as exceptional or world-class, across all evaluated dimensions, including vision and strategy implementation, ethical decision-making, encouraging innovation, originality of research methodology, interdisciplinary research, and real-world application potential. Global Recognition Awards evaluates nominees using the Rasch model, a psychometric measurement system that constructs a linear scale across multiple categories, enabling precise comparisons between applicants who may excel in different areas, and SecretomeTx’s scores held up under that rigorous standard.

The company’s research leadership model involves coordinating scientists, manufacturing teams, clinicians, and regulatory experts within a deliberately interdisciplinary structure that accelerates the path from discovery to the clinic. SecretomeTx’s scientific approach is built on systematic, reproducible work, including comparative studies across manufacturing platforms, stability assessments, and compatibility evaluations that together provide a regulatory foundation capable of withstanding FDA scrutiny. The nCPC platform represents a genuinely novel class of therapy, harnessing the regenerative and immunomodulatory properties of neonatal cardiac-derived cells to activate the body’s natural repair mechanisms, thereby distinguishing it mechanistically from conventional cell replacement approaches and strengthening its scientific credibility.

Final Words

SecretomeTx’s trajectory from a small Baltimore-based startup to a clinical-stage company with FDA Fast Track status, commercial-scale manufacturing partnerships, and an active Phase 1 trial reflects deliberate decisions about where to invest scientific and organizational effort, particularly the early prioritization of manufacturing scalability when most early-stage biotechnology companies defer that work. The company’s ability to execute across research, leadership, and startup growth simultaneously distinguished its application from others evaluated in the same field. Mishra and the SecretomeTx team have demonstrated that rigorous science and operational discipline are not competing priorities but mutually reinforcing ones that, when aligned, can carry a young company from concept to clinic with remarkable speed.

“Secretome Therapeutics exemplifies what it means to operate at a world-class level,” said Alex Sterling, a spokesperson for Global Recognition Awards. “Its combination of first-in-class science, scalable manufacturing strategy, and a leadership culture built on collaboration and mentorship represents exactly the standard of excellence this award was created to recognize.”SecretomeTx’s 2026 Global Recognition Award in the Startup Of The Year, Leadership, and Research categories reflects not only what the company has built but also the credibility of the path it has established for the broader field of regenerative medicine.